Geriatric Inflammatory Bowel Disease: Phenotypic Presentation, Treatment Patterns, Nutritional Status, Outcomes, and Comorbidity

• Published in: Digestive diseases and sciences 2012-09, Vol.57 (9), p.2408-2415
• Main Authors: Juneja, Manie, Baidoo, Leonard, Schwartz, Marc B., Barrie, Arthur, Regueiro, Miguel, Dunn, Michael, Binion, David G.
• Format: Article
• Language: English
• Subjects: Adalimumab; Aged; Aged patients; Aged, 80 and over; Alfacalcidol; Biochemistry; Calcifediol; Comorbidity; Female; Gastroenterology; Hepatology; Humans; Inflammatory bowel disease; Inflammatory Bowel Diseases - drug therapy; Inflammatory Bowel Diseases - pathology; Male; Medical records; Medical research; Medicine; Medicine & Public Health; Medicine, Experimental; Mesalamine - therapeutic use; Nutritional Status; Oncology; Original Article; Parasympatholytics - therapeutic use; Patient outcomes; Purines - therapeutic use; Transplant Surgery; Treatment Outcome; Ulcerative colitis; Vitamin D
• ISSN: 0163-2116; 1573-2568
• DOI: 10.1007/s10620-012-2083-x

Background and Aims The U.S. population is aging and the burden of geriatric inflammatory bowel disease (IBD) patients has increased. Systematic data describing phenotypic presentation, treatment regimens, outcomes and comorbidities in elderly IBD patients is limited. We performed a retrospective observational study of IBD patients age ≥65 followed in a 20-hospital system to determine patterns of phenotypic presentation, treatment, polypharmacy, nutritional status and comorbidity. Methods Data were extracted from electronic medical record based on ICD-9 coding/indexed terms on Crohn’s disease (CD) and ulcerative colitis (UC) patients. Results A total of 393 geriatric IBD patients were identified (49.1% males; 50.9% females; 61.8% UC; 38.2% CD; 73.4 ± 6.6 years old). Younger age at diagnosis of CD (≤64) was associated with greater prevalence of small bowel surgeries (63.6%) compared with those diagnosed after age ≥65 (20.9%) ( p